Citations

Clear

5 citation(s) found for "Ali, Walid".

Artificial intelligence in valvular heart disease: current evidence and future perspectives
Suc, Gaspard , Sengupta, Partho P. , Ali, Walid Ben , Piazza, Nicolò , Burwash, Ian G. , Theriault‐Lauzier, Pascal , Avram, Robert , Bruce, Charles J. , Bohbot, Yohann , Dreyfus, Julien , Enriquez‐Sarano, Maurice , Modine, Thomas , Messika–Zeitoun, David

Mayo Clinic

European Heart Journal - Valvular and Structural Heart Disease | September 8, 2025 | Volume: 1 | Issue: 1 | Pages: No page available

10.1093/ehjvshd/xwaf002 Get It

Abstract Valvular heart disease (VHD) is emerging as the next major epidemic in cardiovascular care, driven by the ageing population. The advent of less invasive alternatives to surgery—namely, transcatheter therapies—has revolutionized patient management, while simultaneously introducing new layers of complexity. Artificial intelligence (AI) holds significant promise to transform the care of patients with VHD across all dimensions, including diagnosis, prognostication, disease progression, and therapeutic decision-making. In this review, we provide a comprehensive overview of the current evidence, and discuss the challenges, risks, and future directions associated with the integration of AI in the management of VHD.
Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli
Tchétché, Didier , Blackman, Daniel J. , Khalil, Ramzi F., Möllmann, Helge , Abdel‐Wahab, Mohamed , Ali, Walid Ben, Mahoney, Paul, Ruge, Hendrik, Lin, Lang, Byku, Isida , Gillam, Linda D. , Petronio, Anna Sonia , Attizzani, Guilherme F. , Batchelor, Wayne , Gada, Hemal, Rovin, Joshua D. , Benton, Stewart M., Gardner, Blake, Padang, Ratnasari , Herrmann, Howard C., Ruge, Hendrik , Ali, Walid Ben , Mehran, Roxana , Khalil, Ramzi F. , Bleiziffer, Sabine , Szerlip, Molly , Grubb, Kendra J , Guerrero, Mayra , Rogers, Toby , Whisenant, Brian K. , Althouse, Andrew D. , Herrmann, Howard C.

Mayo Clinic

JAMA Cardiology | October 9, 2024 | Volume: 9 | Issue: 12 | Pages: 1106

10.1001/jamacardio.2024.3241 | PMID 39382856 Get It

Importance Historically, women with aortic stenosis have experienced worse outcomes and inadequate recognition compared to men, being both underdiagnosed and undertreated, while also facing underrepresentation in clinical trials. Objective To determine whether women with small aortic annuli undergoing transcatheter aortic valve replacement have better clinical and hemodynamic outcomes with a self-expanding valve (SEV) or balloon-expandable valve (BEV). Design, Setting, Participants The Small Annuli Randomized to Evolut or SAPIEN Trial (SMART) was a large-scale randomized clinical trial focusing on patients with small aortic annuli undergoing transcatheter aortic valve replacement, randomized to receive SEVs or BEVs and included 716 patients treated at 83 centers in Canada, Europe, Israel, and the US from April 2021 to October 2022. This prespecified secondary analysis reports clinical and hemodynamic findings for all 621 women enrolled in SMART. Data for this report were analyzed from February to April 2024. Interventions Transcatheter aortic valve replacement with an SEV or a BEV. Main Outcomes and Measures The composite coprimary clinical end point comprised death, disabling stroke, or heart failure–related rehospitalization. The coprimary valve function end point was the incidence of bioprosthetic valve dysfunction, both assessed through 12 months. Secondary end points included the incidence of moderate or severe prosthesis-patient mismatch. Results A total of 621 women (mean [SD] age, 80.2 [6.2] years; 312 randomized to the SEV group and 309 to the BEV group) were included in the present analysis. At 12 months, there were no significant differences in the coprimary clinical end point between the SEV and BEV groups (9.4% vs 11.8%, absolute risk difference −2.3%; 95% CI −7.2 to 2.5, P = .35). However, SEV implantation was associated with less bioprosthetic valve dysfunction (8.4% vs 41.8%; absolute risk difference, −33.4%; 95% CI, −40.4 to −26.4; P < .001). SEV implantation resulted in lower aortic valve gradients and larger effective orifice areas at 30 days and 12 months and less mild or greater aortic regurgitation at 12 months compared to BEV implantation. Prosthesis-patient mismatch was significantly lower with SEVs, regardless of the definition used and adjustment for body mass index. Use of SEVs was associated with better quality of life outcomes as assessed by the Valve Academic Research Consortium-3 ordinal quality of life measure. Conclusions and Relevance Among women with severe symptomatic aortic stenosis and small aortic annuli undergoing transcatheter aortic valve replacement, the use of SEVs, compared to BEVs, resulted in similar clinical outcomes and a markedly reduced incidence of bioprosthetic valve dysfunction through 12 months, including a lower risk of prosthesis-patient mismatch and better 12-month quality of life. Trial Registration ClinicalTrials.gov Identifier: NCT04722250
1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience
Begna, Kebede H. , Ali, Walid , Gangat, Naseema , Elliott, Michelle A. , Al‐Kali, Aref , Litzow, Mark R. , Hook, C. Christopher , Wolanskyj, Alexandra P., Patnaik, Mrinal M. , Pardanani, Animesh , Zblewski, Darci, He, Rong , Viswanatha, David S., Hanson, Curtis A. , Tefferi, Ayalew , Hogan, William J. , Chen, Dong , Ketterling, Rhett P.

Mayo Clinic

Blood | October 14, 2019 | Volume: 132 | Issue: Supplement 1 | Pages: 2689-2689

10.1182/blood-2018-99-110811 Get It

Abstract Background : Pre-treatment determinants of survival in adult acute myeloid leukemia (AML) include performance status, age, karyotype, the distinction between primary and non-primary AML and FLT3-ITD/NPM1 mutational status. Current literature on AML natural history and risk factors is often based on information derived from stringent protocol studies. In the current series of 1,123 adult patients seen at the Mayo Clinic between 2004 and 2017, we examined long-term survival specified by a number of primarily established risk factors. Methods: Diagnosis of AML and its sub-classification was according to World Health Organization criteria. Study subjects were recruited from the Mayo Clinic AML database. Conventional response criteria were used for CR and CRi assignment; the latter met all criteria for CR with the exception of platelet count <100 x 109/l or absolute neutrophil cunt <1 x 109/l. Standard statistical methods were used for analysis of overall survival, calculated from the initial diagnosis of AML to date of death or last follow-up; analyses were performed both in the absence and in the presence of censoring of survival at time of allogenic stem cell transplant (ASCT). The JMP® Pro 13.0.0 software from SAS Institute, Cary, NC, USA, was used for all calculations. Results: 1,123 adult patients (median age 65 years, range 18-94; 61% males) with non-APL AML were considered; 61% were age >60 years. 351 (31%) patients were seen between 2004 and 2009 and 772 (69%) between 2010 and 2017. AML subcategories were primary (56%), post-myelodysplastic syndromes (post-MDS; 24%), therapy-related (10%), post-myeloproliferative neoplasm (post-MPN; 8%) and post-MDS/MPN (3%). Cytogenetic risk distribution, according to the European LeukemiaNet classification, was favorable in 47 (4%), intermediate in 650 (58%) and adverse risk in 426 (38%) patients. FLT3, NPM1 and CEBPA mutation information was available in 462 (24% mutated), 393 (27% mutated) and 228 (11% mutated) patients, respectively. Treatment included intensive chemotherapy (IC) in 766 (68%) patients, less aggressive chemotherapy, including the use of hypomethylating agents in 144 (13%) and supportive care alone in 213 (19%) patients. ASCT was utilized in 258 (23%) cases, almost all performed after achieving CR/CRi. Complete remission (CR) and CR with incomplete count recovery (CRi) were listed in 333 (30%) and 248 (22%) patients, respectively; the corresponding rates in IC-treated patients were 43% and 32%. Almost all cases of CR/CRi occurred in IC-treated patients; 2 (1.4%) CRs were listed for less aggressive chemotherapy. After a median follow-up of 11 months, 798 (71%) deaths were recorded. Median survival for all 1,123 patients was 14 months with 1-, 3- and 5-year survival rates of 54%, 29% and 23%, respectively; a slight but significant (p=0.01) improvement in survival was apparent in more recent years (Figure 1a). Figures 1b, 1c and 1d depict analysis stratified by AML subcategories, treatment received and response obtained, respectively. Similarly, figures 2a, 2b and 2c depict analysis stratified by karyotype, use of ASCT and age. Multivariable analysis of pre-treatment parameters evaluable in all 1,123 patients identified age >60 years (HR 2.2, 1.9-2.6), adverse karyotype (HR 2.9, 1.9-4.9), intermediate-risk karyotype (HR 1.6, 1.02-2.6), post-MPN AML (HR 1.9, 1.5-2.4) and other secondary AML (HR 1.3 (1.1-1.6), as risk factors for shortened survival; the inclusion in the model of FLT3/NPM1 mutational status in 392 informative cases confirmed the adverse prognostic effect of age >60 years (HR 1.8, 1.4-2.5), adverse karyotype (HR 3.7, 1.4-15.3), post-MPN AML (HR 2.8, 1.6-4.6), other secondary AML (HR 1.4, 1.0-1.9) and FLT3+NPM1- (HR 2.8, 1.6-4.9) and FLT3-NPM1- (HR 1.7, 1.2-2.7) profile. Results were unchanged when survival was censored at time of ASCT. Additional prognostic interaction with treatment strategy and ASCT is further elaborated in an accompanying abstract to be presented. Conclusions: The current study, the largest coming from a single institution, provides practically useful information that should assist with patient consultation on AML prognosis and treatment. The study confirms the primary prognostic importance of age, karyotype and FLT3/NPM1 mutational status, in real-life practice. Novel observations included comparable value of CRi vs CR and the particularly worse prognosis associated with post-MPN AML. Disclosures Al-Kali: Novartis: Research Funding.
A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3‐ITD mutational status
Begna, Kebede H. , Ali, Walid , Gangat, Naseema , Elliott, Michelle A. , Al‐Kali, Aref , Litzow, Mark R. , Hook, C. Christopher , Wolanskyj, Alexandra P. , Patnaik, Mrinal M. , Pardanani, Animesh , Zblewski, Darci, Chen, Dong , He, Rong , Viswanatha, David S., Hanson, Curtis A. , Tefferi, Ayalew , Patnaik, Mrinal , Zblewski, Darci L, Chen, Dong , Viswanatha, David, Tefferi, Ayalew , Wolanskyj-Spinner, Alexandra P , Hogan, William J. , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | September 19, 2018 | Volume: 93 | Issue: 12 | Pages: No page available

10.1002/ajh.25290 | PMID 30230610 Get It